Strategies to Overcome Challenges in Commercializing Treatments for Rare Diseases
By Kelly Cockerill, Vice President, Marsha Pelletier, Director, Philippe De Gaiffier, Consultant, and Carrie Jones, Partner
Rare Disease Day serves as a reminder of the ongoing collaborative effort in the healthcare industry to bring valuable new treatments for the over 300MM global rare disease patients.
Despite the rapidly advancing science and established unmet need for patients, rare disease drug manufacturers face several unique challenges when commercializing new products.
Health Advances, as a strategic healthcare and life sciences consulting firm, helps rare disease drug developers make smart decisions that will best position their products for broad patient access.
In our 30 years of work across the rare disease industry, we’ve identified several key success factors:
Interested in some of these examples? Please reach out to us or follow our blog so you don’t miss our future deep dives on these topics above and many more. https://healthadvancesblog.com
Contact
Carrie Jones cjones@healthadvances.com, Partner leads Health Advances’ Rare and Orphan Disease Practice.
###
Related Insights
Blog
Optimize your post-approval CMC change management in China with the ICH Q12 tool
Nov 24, 2025
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
New CNS Franchise Leader brings experience from pharma and as a clinician and researcher
Nov 14, 2022
Podcast
FSP Podcast Series | Episode 2: Celebrating a 25-Year Career with Kerri McCaul-Claus
Dec 6, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Blog
The New Frontier of Innovative Therapies: Navigating What's Next
Jan 12, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Whitepaper
Optimizing Biosensor-based Trials
Feb 1, 2023
Video
Ensure End to End and Vein to Vein Success for your Clinical Trial Supply Chain
Oct 14, 2022
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Related Insights
Blog
Optimize your post-approval CMC change management in China with the ICH Q12 tool
Nov 24, 2025
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
New CNS Franchise Leader brings experience from pharma and as a clinician and researcher
Nov 14, 2022
Podcast
FSP Podcast Series | Episode 2: Celebrating a 25-Year Career with Kerri McCaul-Claus
Dec 6, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Blog
The New Frontier of Innovative Therapies: Navigating What's Next
Jan 12, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Whitepaper
Optimizing Biosensor-based Trials
Feb 1, 2023
Video
Ensure End to End and Vein to Vein Success for your Clinical Trial Supply Chain
Oct 14, 2022
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023